Kathryn Chenault, MD
Neurology · Sherwood, ARNPI 1942290481
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $440,229 of the $531,761 with a category attached, or 82.8%. 45 manufacturers reported payments, led by EMD Serono, Inc. at 55.2% of the total. Among neurology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,536 payments — averaging $346.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$294K
- Biogen$83K
- AstraZeneca$47K
- TG Therapeutics, Inc.$39K
- Sanofi$38K
- Genentech USA, Inc.$18K
- plus $12K from 39 others
What the payments were for
- Consulting fees$43,4288%
- Speaking & faculty fees$440,22983%
- Travel & lodging$18,7194%
- Food & beverage$29,1555%
- Education$2290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$531,761 in reported general payments places this provider in the 95th percentile of 93 neurology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 68 | $656,517 |
| SolirisEculizumab | 17 | $464,272 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $289,782 |
| AubagioTeriflunomide | 18 | $245,317 |
| RebifInterferon Beta-1a/Albumin | 16 | $171,413 |
| PlegridyPeginterferon Beta-1a | 19 | $155,062 |
| VumerityDiroximel Fumarate | 14 | $140,212 |
| CopaxoneGlatiramer Acetate | 19 | $111,594 |
| QuliptaAtogepant | 79 | $91,579 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 16 | $80,130 |
| Nurtec OdtRimegepant Sulfate | 53 | $73,972 |
| NuplazidPimavanserin Tartrate | 13 | $66,230 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $63,348 |
| Aimovig AutoinjectorErenumab-Aooe | 79 | $62,359 |
| TopamaxTopiramate | 13 | $49,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $46,927 | $464,27217 claims |
| BiogenPlegridy, Vumerity | $83,205 | $295,27533 claims |
| SanofiAubagio | $38,395 | $245,31718 claims |
| EMD Serono, Inc.Rebif | $293,716 | $171,41316 claims |
| PfizerNurtec Odt, Octagam | $825 | $137,31966 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $219 | $111,59419 claims |
| AbbVieQulipta, Ubrelvy | $949 | $110,48298 claims |
| Acadia Pharmaceuticals IncNuplazid | $149 | $66,23013 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $283 | $31,73416 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $519 | $23,31485 claims |
| UCB, Inc.Neupro | $404 | $9,89612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 neurology providers in Arkansas.
Other neurology in Sherwood
- Steve-Felix BelingaFort Smith$183K
- Michael MorseFayetteville$149K
- Mark PippengerNorth Little Rock$109K
- Kara WayHot Springs$72K
- Keith SchlutermanConway$67K
- Shitiz SriwastavaLittle Rock$59K
- Ronald SouthJonesboro$59K
- Elizabeth SullivanLittle Rock$33K
- Ahmad Al-KhatibBentonville$30K
- Timothy FreyaldenhovenConway$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.